En Es
Categories

Industry News

GE Launches Drawbridge Health to Transform Blood Collection

By Labmedica International staff writers
05 Dec 2017

Image: GE’s new Drawbridge solution will eliminate the need for phlebotomy and travel to blood draw centers (Photo courtesy of iStock).GE Healthcare (Chicago, IL, USA) has introduced Drawbridge Health, a privately held healthcare technology company, which is developing a people-friendly system to integrate draw, collection and stabilize blood samples into a single device. The technology which integrates engineering and proprietary chemistries is also being developed to support room temperature shipping and streamlined downstream processing, thus ensuring reliable, accurate results.

The Drawbridge solution will allow healthcare providers and diagnostic testing companies to deliver a superior patient experience by eliminating the need for phlebotomy and travel to blood draw centers. Drawbridge expects its blood draw solution to alter the market for patients and healthcare providers by broadening the availability and access for molecular tests for a variety of diseases, as well as providing a convenient way to monitor overall health, therapy response and disease progression.

“At GE we share technology, markets, structure and knowledge across our varied businesses, which uniquely positions us to tackle many issues, including this one,” said Risa Stack, Managing Director of New Business Creation, GE Ventures. “With Drawbridge Health, we are combining technology from GE Global Research, expertise from GE Healthcare and business models from GE Ventures to offer a simple, safe and more efficient solution that can help save time, money and lives.”

“At Drawbridge Health, we have a tremendous opportunity to uniquely enable not only effortless access to diagnostic testing, but to also transform how diagnostics companies and healthcare providers interact with their patient-consumers,” said Lee McCracken, CEO, Drawbridge Health.

“The current sample testing process is inconvenient and challenging for patients and medical providers, alike. It requires clinical processing equipment, often a technician specifically trained to draw blood, plus a trip to the doctor’s office or hospital. By combining world class GE technology and a talented founding team to address an important market need, Drawbridge Health is well positioned to transform diagnostic testing for healthcare stakeholders, testing laboratories, patients and consumers.”



E-mail Print
FaceBook Twitter Google+ Linked in

GE Healthcare

GE Healthcare provides medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services. The company’s product areas include anesthesia delivery, diagnostic ECG, mammography, radiography, surgical imaging, maternal-infant care and clinical consumables.
More info

More articles about GE Healthcare

30 Jan 2020
Study Finds Most Healthcare Institutions Plan to Use AI and Develop Own AI Algorithm
 A new study of healthcare professionals has revealed that Artificial Intelligence (AI) is widely expected to drive important benefits across the health system, from increasing efficiency to improving patient outcomes, but may also be the key to making healthcare more human. AI’s benefits range from increasing the amount of time clinicians can spend with patients and on cross-care team collaboration to enhancing the ability to deliver preventative care.
Read More
26 Sep 2019
GE Healthcare and Affibody Collaborate to Develop PET Imaging Tracers
GE Healthcare and Affibody AB have entered into a strategic collaboration to develop and commercialize Affibody-based PET imaging tracers, with initial focus on HER2 and PD-L1.
Read More
22 Aug 2019
GE Healthcare Partners with Fujitsu to Develop AI for Spotting Brain Aneurysms
GE Healthcare has entered into a research collaboration with Fujitsu Australia to diagnose and monitor brain aneurysms on scans faster and more efficiently by using artificial intelligence.
Read More
03 May 2019
First Deep Learning-Based Image Reconstruction Technology Receives FDA Clearance
GE Healthcare has received 510(k) clearance from the U.S. FDA for its Deep Learning Image Reconstruction (DLIR) engine on its new Revolution Apex CT device, and as an upgrade to its Revolution CT system in the U.S.
Read More
18 Oct 2018
GE Healthcare and ESR Enter AI Partnership for ECR 2019
GE Healthcare (Chicago, IL, USA) and the European Society of Radiology (Vienna, Austria) will be partnering on artificial intelligence (AI) for the upcoming European Congress of Radiology (ECR) to be held in Vienna, Austria on February 27-March 3, 2019. The partnership will include joint sessions on AI and a dedicated space at GE Healthcare’s booth where visitors will be able to experience the AI transformation through interactive tools.
Read More
15 Oct 2018
GE Healthcare to Implement First AI-Powered Hospital Command Centers
GE Healthcare is collaborating with hospital service providers in Europe and the US for implementing an artificial intelligence (AI)-powered command center to effectively and efficiently synchronize all elements of a patient's hospital experience. The AI-powered system will support caregivers to enhance patient safety, orchestrate seamless care delivery and get patients back home sooner.
Read More
26 Jun 2018
GE to Spin Off Healthcare Business
In line with a sweeping strategic reorganization, General Electric Company has announced the decision to spin off its Healthcare business segment as an independent company. The move comes on the heels of a lengthy managerial review conducted by GE management under newly appointed CEO John Flannery.
Read More
16 Jan 2018
GE Healthcare and Roche Partner to Develop Digital Diagnostics Platform
GE Healthcare and Roche have entered into a strategic, long-term partnership to jointly develop and co-market digital clinical decision support solutions. Initially, the partnership will focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Read More

Additional news

17 Feb 2020
New System Combines Advanced Optical Imaging with AI Algorithm to Accurately Identify Brain Tumors
 Researchers from the NYU Grossman School of Medicine (New York, NY, USA) and the University of Michigan (Ann Arbor, MI, USA) have developed a novel method of combining advanced optical imaging with an artificial intelligence (AI) algorithm to produce accurate, real-time intraoperative diagnosis of brain tumors. The imaging technique, stimulated Raman histology (SRH), reveals tumor infiltration in human tissue by collecting scattered laser light, illuminating essential features not typically seen in standard histologic images. The microscopic images are then processed and analyzed with AI, allowing surgeons to see a predicted brain tumor diagnosis in less than three minutes. Using the same technology, after the resection, the surgeons can accurately detect and remove otherwise undetectable tumor.
Read More
10 Feb 2020
Global Medical Robotics Market to Reach USD 13.90 Billion by 2026
 The global medical robotics market is projected to grow at a double-digit CAGR from 2019 to 2026 to reach USD 13.90 billion by 2026, driven by the increasing demand for minimally invasive surgery, rising prevalence of gynecology, urology and orthopedic disorders, increasing aging population, technological innovations, growing adoption of medical robots among the population and increasing clinical trials.
Read More
04 Feb 2020
Patient Handling Equipment Market to Reach USD 12.6 Billion by 2024
 The global patient handling equipment market is projected to grow at a CAGR of 7.2% from USD 8.9 billion in 2019 to USD 12.6 billion by 2024, driven mainly by the rising geriatric population, high risk of injuries to caregivers during manual handling of patients, and regulations for ensuring the safety of healthcare personnel during manual lifting processes. However, continued difficulties in handling bariatric patients are expected to limit the market growth to some extent.
Read More
30 Jan 2020
Quest Diagnostics Acquires Blueprint Genetics
 Quest Diagnostics (Secaucus, NJ, USA), a provider of diagnostic information services, has acquired Blueprint Genetics (Helsinki, Finland), a specialty genetic testing company with expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development.
Read More
27 Jan 2020
JNJ Acquires Remaining Stake in Verb Surgical
 Johnson & Johnson (New Brunswick, N.J., USA) has acquired the remaining stake in Verb Surgical Inc. (Santa Clara, CA, USA), following a successful strategic collaboration with Verily, an Alphabet company. Verb Surgical's robotics and data science capabilities, combined with Johnson & Johnson's health care leadership and global reach, aim to make medical interventions smarter, less invasive and more personalized.
Read More
22 Jan 2020
Global Point of Care Testing (POCT) Market to Reach USD 46.7 Billion by 2024
 The global point of care testing (POCT) market is expected to surpass USD 37 billion by 2025, driven mainly by the migration of POCT from the hospital environment to a range of medical environments, including the workplace, home, disaster care and most recently, convenience clinics. POCT now appears to be headed for a bigger role in diagnosis and monitoring patient care. Additionally, growing awareness about early disease diagnosis and prevention has stimulated the demand for POCT for detecting cancer and infectious disease in the early stages. Moreover, the rising incidence of infectious diseases and chronic conditions, such as cardiovascular diseases and diabetes in the developing countries such as India and China, is stimulating the demand for POCT services.
Read More
16 Jan 2020
Radiomic Algorithm Predicts if Patient’s Cancer Can Return 10 Years After Treatment
 A new study by researchers at Penn Medicine (Philadelphia, PA, USA) has found that Magnetic Resonance Imaging (MRI) and an emerging field of medicine called radiomics — which uses algorithms to extract a large amount of features from medical images — could help to characterize the heterogeneity of cancer cells within a tumor and allow for a better understanding of the causes and progression of a person’s individual disease.
Read More
13 Jan 2020
PENTAX Medical Clears CE Mark for New AI-Assisted Polyp Detector
 PENTAX Medical (Tokyo, Japan) has cleared CE mark for DISCOVERY, its Artificial Intelligence (AI) assisted polyp detector designed to support endoscopists in finding potential polyps during a colorectal examination.
Read More
07 Jan 2020
New AI Model Identifies Women Facing Future Risk of Breast Cancer
 Researchers from the Karolinska Institute (Stockholm, Sweden) have developed a sophisticated type of artificial intelligence (AI) which can outperform existing models at predicting which women are at future risk of breast cancer.
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions